LMAN2 and infection: Breast cancer cells could modify the surrounding microenvironment and thereby escape the immune system.37 Compromised immunity is a major issue in breast cancer therapy: the patients receiving adjuvant therapy with doxorubicin and cyclophosphamide are exposed to high risk of grade-3 infection due to the lower mannose-binding lectin 2 expression in their body.38 Supplementation of MBP during anticancer therapy is one of strategies in immunotherapy39 and Abmb could be developed for that purpose.